Cargando…
Novel immunomodulatory drugs and neo-substrates
Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies. Recent studies showed that IMiDs bind to CRBN, a substrate receptor of CRL...
Autores principales: | Gao, Shaobing, Wang, Shichao, Song, Yongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953231/ https://www.ncbi.nlm.nih.gov/pubmed/31938543 http://dx.doi.org/10.1186/s40364-020-0182-y |
Ejemplares similares
-
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
por: Wang, Shichao, et al.
Publicado: (2021) -
NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022) -
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
por: Liu, Jiye, et al.
Publicado: (2021) -
Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment
por: Buonfiglio, Francesco, et al.
Publicado: (2023) -
NEO-NATAL PÆDIATRICS
Publicado: (1959)